Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Japan Lifestyle-Related Disease Treatment Market to Subside, after Peaking in 2018: Fuji Keizai
August 7, 2018
- AnGes’ HGF Therapy Could Debut Before Year-End to Become 1st Gene Therapy in Japan; 2 More Products Anticipated in 2019
August 7, 2018
- Takeda, Whiz Partners to Set Up Joint Investment Fund to Spur Drug Ecosystem
August 6, 2018
- Amgen Astellas Seeks OK for Repatha Monotherapy Use in Statin-Intolerant Patients
August 6, 2018
- Rituxan Filed for Add’l Indication of Chronic Lymphocytic Leukemia
August 6, 2018
- Opdivo Defended Crown with Ono’s Asia Sales Added, but Keytruda Triumph Would Come Soon
August 6, 2018
- AstraZeneca’s Japan Crestor Sales Dive 71%
August 3, 2018
- Ninlaro Production Site Opens in Russia: Takeda
August 3, 2018
- Thrombocytopenia Drug Mulpleta Earns FDA Approval: Shionogi
August 3, 2018
- Recomodulin Fails to Hit Primary Goal in PIII for Severe Sepsis with Coagulopathy: Asahi Kasei
August 3, 2018
- Eisai Neurology Chief Shows Eagerness on Alzheimer’s Combination Trials
August 2, 2018
- AstraZeneca’s AI Translation System Could Bring Huge Impact If Materialized: Japan R&D Chief
August 2, 2018
- Opdivo Sales Up 15% in April-June: Ono
August 2, 2018
- Daiichi Sankyo’s FLT3 Inhibitor Grabs FDA’s Breakthrough Therapy Status
August 2, 2018
- Kyowa Kirin Hopeful of PIII Study of Sakigake Designated DKD Treatment: President
August 2, 2018
- Kyorin Awards Spanish Pharma Rights to Uritos in Latin America
August 2, 2018
- Rxulti Gets European Approval for Schizophrenia: Otsuka/Lundbeck
August 1, 2018
- Takeda Completes TiGenix Acquisition
August 1, 2018
- Lenvima-Keytruda Combo Bags FDA’s Breakthrough Status for Endometrial Carcinoma
August 1, 2018
- Kyowa Hakko Kirin to Be Renamed Kyowa Kirin in July 2019
August 1, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…